News >

Research Efforts in HER2+ Breast Cancer Focused on Optimizing Novel Agents

Caroline Seymour
Published: Monday, Nov 18, 2019

Gregory Vidal, MD, PhD, assistant professor, Department of Hematology/Oncology, The University of Tennessee Health Science Center, a medical oncologist at West Cancer Center

Gregory Vidal, MD, PhD

Higher affinity HER2-targeted therapy with margetuximab, more potent TKIs such as tucatinib, and potent antibody-drug conjugates like [fam-] trastuzumab deruxtecan are all showing promise in patients with HER2-positive breast cancer, said Gregory Vidal, MD, PhD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication